CIMETIDINE ALTERS THE DISPOSITION KINETICS OF THE MONOAMINE OXIDASE-A INHIBITOR MOCLOBEMIDE

被引:22
作者
SCHOERLIN, MP
MAYERSOHN, M
HOEVELS, B
EGGERS, H
DELLENBACH, M
PFEFEN, JP
机构
[1] UNIV ARIZONA,COLL PHARM,TUCSON,AZ 85721
[2] F HOFFMANN LA ROCHE & CO LTD,DEPT CLIN PHARMACOL,CH-4002 BASEL,SWITZERLAND
[3] F HOFFMANN LA ROCHE & CO LTD,CLIN PHARMACOL UNIT,CH-4002 BASEL,SWITZERLAND
[4] UNIV ARIZONA,COLL PHARM,TUCSON,AZ 85721
关键词
D O I
10.1038/clpt.1991.6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of cimetidine on the absorption and disposition of moclobemide was examined in eight healthy male subjects. A single 100 mg intravenous and 100 mg oral dose of moclobemide was administered before and after 2 weeks of cimetidine administration (200 mg five times a day). The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours. There was no significant difference in the steady-state volume of distribution. The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml). There were no differences in the mean absorption time or time to achieve maximum concentration. The values of systemic and apparent oral clearances of moclobemide after cimetidine administration were directly related to the corresponding control values before cimetidine. In contrast, the percentage change in clearance was essentially independent of the corresponding initial control clearance value.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 27 条
[1]   EFFICACY AND TOLERABILITY OF MOCLOBEMIDE COMPARED WITH IMIPRAMINE IN DEPRESSIVE DISORDER (DSM-III) - AN AUSTRIAN DOUBLE-BLIND, MULTICENTER STUDY [J].
BAUMHACKL, U ;
BIZIERE, K ;
FISCHBACH, R ;
GERETSEGGER, C ;
HEBENSTREIT, G ;
RADMAYR, E ;
STABL, M .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 155 :78-83
[2]   NONCOMPARTMENTAL DETERMINATION OF THE STEADY-STATE VOLUME OF DISTRIBUTION [J].
BENET, LZ ;
GALEAZZI, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1071-1074
[3]   DETERMINATION AND COMPARISON OF THE PRESSOR EFFECT OF TYRAMINE DURING LONG-TERM MOCLOBEMIDE AND TRANYLCYPROMINE TREATMENT IN HEALTHY-VOLUNTEERS [J].
BERLIN, I ;
ZIMMER, R ;
COURNOT, A ;
PAYAN, C ;
PEDARRIOSSE, AM ;
PUECH, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (03) :344-351
[4]   A PLACEBO-CONTROLLED STUDY OF THE ANTIDEPRESSANT ACTIVITY OF MOCLOBEMIDE, A NEW MAO-A INHIBITOR [J].
CASACCHIA, M ;
CAROLEI, A ;
BARBA, C ;
FRONTONI, M ;
ROSSI, A ;
MECO, G ;
ZYLBERMAN, MR .
PHARMACOPSYCHIATRY, 1984, 17 (04) :122-125
[5]  
DAPRADA M, 1982, MONOAMINE OXIDASE BA, P183
[6]   REDUCTION OF LIVER BLOOD-FLOW AND PROPRANOLOL METABOLISM BY CIMETIDINE [J].
FEELY, J ;
WILKINSON, GR ;
WOOD, AJJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (12) :692-695
[7]  
GERBER MC, 1985, PHARMACOL THERAPEUT, V27, P353, DOI 10.1016/0163-7258(85)90075-0
[8]   DETERMINATION OF THE NEW MONOAMINE-OXIDASE INHIBITOR MOCLOBEMIDE AND 3 OF ITS METABOLITES IN BIOLOGICAL-FLUIDS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
GESCHKE, R ;
KORNER, J ;
EGGERS, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 420 (01) :111-120
[9]   EFFECT OF MOCLOBEMIDE, A NEW REVERSIBLE MONOAMINE-OXIDASE INHIBITOR, ON ABSORPTION AND PRESSOR EFFECT OF TYRAMINE [J].
KORN, A ;
DAPRADA, M ;
RAFFESBERG, W ;
GASIC, S ;
EICHLER, HG .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 11 (01) :17-23
[10]   RAPID METHOD FOR DETERMINATION OF CIMETIDINE IN BIOLOGICAL-FLUIDS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY USING EXTRELUT EXTRACTION [J].
KOZMA, M ;
VERECZKEY, L .
JOURNAL OF CHROMATOGRAPHY, 1983, 273 (01) :223-227